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ABSTRACT
Introduction: Women are largely unaware that
mammography screening can cause overdetection of
inconsequential disease, leading to overdiagnosis and
overtreatment of breast cancer. Evidence is lacking
about how information on overdetection affects
women’s breast screening decisions and experiences.
This study investigates the consequences of providing
information about overdetection of breast cancer to
women approaching the age of invitation to
mammography screening.
Methods and analysis: This is a randomised
controlled trial with an embedded longitudinal
qualitative substudy. Participants are a community
sample of women aged 48–50 in New South Wales,
Australia, recruited in 2014. Women are randomly
allocated to either quantitative only follow-up (n=904)
or additional qualitative follow-up (n=66). Women in
each stream are then randomised to receive either the
intervention (evidence-based information booklet
including overdetection, breast cancer mortality
reduction and false positives) or a control information
booklet (including mortality reduction and false
positives only). The primary outcome is informed
choice about breast screening (adequate knowledge,
and consistency between attitudes and intentions)
assessed via telephone interview at 2 weeks
postintervention. Secondary outcomes measured at
this time include decision process (decisional conflict
and confidence) and psychosocial outcomes
(anticipated regret, anxiety, breast cancer worry and
perceived risk). Women are further followed up at
6 months, 1 and 2 years to assess self-reported
screening behaviour and long-term psychosocial
outcomes (decision regret, quality of life). Participants
in the qualitative stream undergo additional in-depth
interviews at each time point to explore the views and
experiences of women who do and do not choose to
have screening.
Ethics and dissemination: The study has ethical
approval, and results will be published in peer-
reviewed journals. This research will help ensure that
information about overdetection may be communicated
clearly and effectively, using an evidence-based
approach, to women considering breast cancer
screening.
Trial registration number: Australian New Zealand
Clinical Trials Registry ACTRN12613001035718.
INTRODUCTION
While mammography screening can reduce
breast cancer mortality, it also carries the risk
of overdetection (or overdiagnosis). This
occurs when screening detects a cancer that
would not have presented clinically during
the woman’s lifetime, meaning she would
never have acquired a diagnosis had she not
Strengths and limitations of this study
▪ This longitudinal mixed-methods study includes
a randomised controlled trial and a qualitative
substudy. Participants are sampled randomly
and are making real-life decisions. The interven-
tion rests on strong evidence (updated published
model of screening outcomes incorporating local
data) including extensive qualitative research.
The primary outcome is informed choice, and
data are collected by an independent non-profit
company.
▪ Our estimates of the effects of screening are
drawn from trials conducted overseas and in the
past. The intervention may not address the
needs of some population groups such as
people with low literacy.
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attended screening. Overdetection and the resulting
overtreatment are likely to cause harm in terms of emo-
tional well-being,1 physical health in the short term and
long term2 and implications for relatives consequently
classiﬁed as high risk.3 4
The problems of overdiagnosis and overtreatment in
cancer screening5 and the broader health context6 are
receiving increasing attention. In the UK, an independ-
ent expert panel was commissioned in 2011 to review
evidence on important consequences of breast screen-
ing, including the challenging task of quantifying the
level of overdetection. Wide variations among previous
estimates had prompted extensive debate over the
appropriateness of different observational methods and
their associated biases.7–9 Focusing on randomised trials
as the best quality evidence, the panel concluded that
invitation to screening leads to overdetection of breast
cancer at a rate of 19% during the 20-year screening
period.10
Historically, information materials distributed by
breast screening programmes worldwide have empha-
sised beneﬁts and lacked explanation of overdetec-
tion.11–14 The appropriateness of explicitly informing
people about overdetection has been debated, with
reluctance driven by concerns about dissuading women
from screening.15 16 However, in the context of a
growing international movement towards policies pro-
moting greater involvement of patients and citizens in
health decision-making17–20 it has been argued that
people offered screening should have the opportunity to
make informed decisions about whether to participate.
Making an informed decision about screening
requires clear, balanced information on beneﬁts and
harms.10 20–23 A new approach to public information was
recently adopted in the UK with the aim of better sup-
porting informed choice,24 and the new UK breast
screening leaﬂet released in September 2013 acknowl-
edges overdetection as ‘the main risk of screening’.25
Given the current lack of awareness of overdetection,26–30
such a change to public information is signiﬁcant and
there is a need for high-quality research into its effects.
Breast screening is a highly emotive issue, as demon-
strated by the public outrage unleashed when the US
Preventive Services Task Force changed its recommenda-
tions in 2009.31–33 Moves to include overdetection in
screening information materials stand to affect large
numbers of women around the world. Research is
needed to ensure important messages are not miscon-
strued in ways that adversely affect women’s health and
well-being.
There is little research on public responses to overde-
tection. In a focus group study,27 we examined 50
women’s understanding of overdiagnosis, screening atti-
tudes and intentions and views on information provi-
sion. Participants were previously unaware of
overdetection but able to understand it. Although sur-
prised, women valued the information about overdetec-
tion. These ﬁndings were corroborated by a similar UK
study.30 As some women in our study indicated that
knowing about overdetection may change their screen-
ing or treatment decisions,27 a careful and balanced
approach to communication is critical.
The current population-based trial extends our investi-
gation of the impact of overdetection information into a
real-life decision-making setting. Using a longitudinal,
randomised design incorporating quantitative and quali-
tative methods, the trial examines the impact of written
information about screening outcomes (breast cancer
deaths averted and false positives, either including or
excluding overdetection) among women close to the
target age for entering Australia’s screening programme.
In addition to examining how the information affects
women’s decisions, attitudes, psychological responses
and well-being in the short term, we will follow partici-
pants for 2 years to assess effects on screening participa-
tion and to qualitatively investigate the long-term impact
of this information in women who do and do not
choose to be screened.
Aims
We will examine and evaluate the impact of information
about overdetection in breast screening on:
1. informed choice—measured via knowledge, attitudes
and intentions;
2. decision process (decisional conﬂict and
conﬁdence);
3. short-term psychosocial outcomes (anxiety, risk per-
ceptions, breast cancer worry, anticipated regret);
4. screening attendance over 2 years;
5. experience of screening for those who attend;
6. long-term psychosocial outcomes (decision regret,
quality of life).
METHODS AND ANALYSIS
Study design
The study uses a randomised trial design with conven-
tional quantitative outcomes plus an embedded longitu-
dinal qualitative substudy (streams A (quantitative) and B
(qualitative)—see ﬁgure 1). This design ensures we can
(1) quantify the impact of overdetection information on
women’s immediate screening decision-making and (2)
assess behaviour and psychosocial outcomes throughout
the 2-year follow-up period, allowing us to contextualise
experiences and capture changes over time among
women who ultimately choose to screen or not screen.
Since it is plausible that the qualitative interviews
could inﬂuence responses to the quantitative measures
(even by simply reminding women of breast screening),
we have separated the cohorts entirely so that our quan-
titative dataset will not include any women who are part
of the qualitative component of the research. Both
streams will follow the same procedure including all
quantitative measures completed via telephone, but
women in the qualitative stream will be invited for add-
itional interviews at the time points speciﬁed.
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Setting and participants
Study participants will be a community sample of
women aged 48–50 years from the Australian state of
New South Wales (NSW). The government-funded pro-
gramme, BreastScreen NSW, offers a free biennial
screening service and mails a personal invitation to all
women when they turn 50 and enter the target age
range. The study will therefore involve women who are
approaching or at this decision point. This study focuses
on women facing an initial decision about whether to
screen, as our qualitative study found that women’s per-
ceptions of overdetection were inﬂuenced by their previ-
ous screening participation.27
Eligibility criteria
Inclusion criteria
Individuals will be eligible if they are women; aged
48–50 years; residing in NSW and sufﬁciently ﬂuent in
English34 to understand study materials and complete
telephone interviews.
Exclusion criteria
Individuals will be excluded from the trial if they have a
personal history of breast cancer; have had any
mammogram within the previous 2 years or are at
increased risk of breast cancer compared with the
general population, for example due to a strong family
history.35 Women at increased risk will be referred to
their doctor or the Australian Cancer Council’s tele-
phone helpline.
Pilot study
Before the main trial, a pilot study will be carried out
with approximately 30 women to test the recruitment
and data collection procedures up to the 2-week tele-
phone survey, including checking the suitability of the
telephone interview scripts.
Participant recruitment
We will recruit by sampling from a random extract of
women in the appropriate age group, drawn from the
NSW electoral register. Recruitment will be carried out
via telephone by the Hunter Valley Research Foundation
(HVRF), an independent non-proﬁt organisation with
extensive experience running community surveys and
successfully recruiting participants into health research
studies.27 36
Figure 1 Design of randomised controlled trial with longitudinal qualitative substudy.
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A database containing names and telephone numbers
will be encrypted and sent to HVRF. Trained HVRF
interviewers will telephone potential respondents and
explain how and why their contact details were obtained.
Interviewers will then brieﬂy introduce the study and
determine eligibility using a series of simple questions.
Eligible women will be informed about what the main
study involves and invited to participate. The trial’s aims
will be described in a general way, as ‘a study to make
sure that written information about breast cancer screen-
ing is clear and helpful to women’, without speciﬁcally
referring to overdetection. Consent will be obtained
orally and documented by the interviewer.
Preintervention procedure and measures
To achieve a common baseline level of information
about screening, immediately after recruitment to the
study all women will be sent the BreastScreen NSW pro-
gramme leaﬂet, a freely available leaﬂet that
BreastScreen sends to women together with their invita-
tions to attend screening.37 As well as outlining practical
aspects of mammography screening, the leaﬂet describes
beneﬁts of early detection while acknowledging the pos-
sibility of a false negative (ie, missed cancer) or false
positive result (ie, abnormal mammogram when there is
no cancer). It does not provide quantitative estimates of
the chances of these outcomes, nor does it mention
overdetection.
After 1 week HVRF will telephone each participant
again, collect demographic information not already
recorded, and check that the woman has received the
leaﬂet and had time to read it. If so, the interviewer will
collect the following baseline data and then proceed to
randomisation:
Stage of decision-making
Women will be asked how far along they are with their
decision about screening, using a single item with four
response options, as used in previous trials of screening
decision aids.38 39
Screening intentions
Women will be asked their intentions about having a
screening mammogram within the next 2–3 years, using
a single item with ﬁve response options (ranging from
deﬁnitely will not to deﬁnitely will).40 41
Screening attitudes
Attitudes towards screening will be measured using a vali-
dated, theory-based generic screening attitudes scale com-
prising six items42 with ﬁve response categories ranging
from strongly disagree to strongly agree (scored 1–5).36
Screening knowledge (conceptual)
Women’s knowledge of the main concepts of screening
will be assessed using items adapted from previous deci-
sion aid trials.36 38 39
If the woman has not yet read the leaﬂet, arrange-
ments will be made to call back at an agreed time. If she
has still not read the leaﬂet by the next contact, she will
be excluded from the trial (prior to randomisation).
The purpose of only including women who have demon-
strated a willingness to read study materials is to maxi-
mise the likelihood that the individuals randomised will
read their allocated intervention and complete the trial,
which is designed to detect any intervention effect
under ideal circumstances. This is appropriate for the
ﬁrst randomised trial of consumer information about
overdetection in breast screening.
Allocation procedures
Randomisation sequences will be generated by a statisti-
cian who has no contact with participants, using per-
muted blocks with sizes of 4 and 8. Interviewers
responsible for recruiting participants will not be aware
of the randomisation sequence or allocation and there-
fore will not know which intervention respondents will
receive.
Randomisation to stream A versus B
During the second telephone contact, participants will
be randomised to either stream A or receive invitation
to the qualitative stream B (described by the telephone
interviewer as an ‘enhanced version’ of the study) to
achieve the desired sample size in each stream (ie, in an
allocation ratio of approximately 13:1). Women who
accept the invitation to stream B will be sent plain-
language written information about the qualitative sub-
study together with their allocated booklet. Women who
decline the invitation to stream B will be included in
stream A.
Randomisation to intervention versus control
Participants within each stream will be allocated to
either the intervention or control arm using permuted
block randomisation with a 1:1 ratio.
Intervention and control arms
The trial will compare two versions of an evidence-based
written information booklet explaining the beneﬁt and
harms of biennial mammography screening from age
50, cumulated over 20 years:
1. Intervention: explanatory information and quantitative
estimates of breast cancer mortality beneﬁt, false
positives (including total number of women with a
false positive, and number having a biopsy) and over-
detection; versus
2. Control: the same explanatory and quantitative infor-
mation about breast cancer mortality beneﬁt and
false positives as in the intervention group but with
NO overdetection information.
The booklet was developed for the purposes of this
study, and is designed to inform but not to inﬂuence
women either towards or away from screening. The
content and presentation were guided by our focus
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group ﬁndings regarding women’s understanding of
overdiagnosis, areas of concern or confusion, and views
on communication (including a preference for the term
overdetection rather than overdiagnosis).27 The booklet
was developed with input from layperson collaborators,
reviewed by independent clinical and communication
experts, and thoroughly piloted for acceptability and
comprehension (details of piloting will be published
separately).
The quantitative evidence presented is based on an
updated version of our published model of screening
outcomes43 using effect estimates from a meta-analysis of
randomised controlled trials,10 adjusted to reﬂect
screening attendance rather than invitation, and applied
to current Australian data. The expected frequencies of
outcomes are illustrated and contextualised using icon
arrays depicting the absolute numbers affected per 1000
women screened over 20 years.44
Table 1 summarises the topics covered in the two ver-
sions of the booklet (for additional detail, see online
supplementary table). Both are identical in format; the
control version was produced directly from the interven-
tion booklet by simply deleting the two pages on overde-
tection and all other references to it (eg, in Q and A
and summary table). The sections on beneﬁt and false
positives are identical across versions in terms of content
and format.
STREAM A: QUANTITATIVE STUDY
Methods of data collection and blinding
Trained HVRF interviewers will conduct a telephone
survey (15–20 min) to collect postintervention outcome
data 2 weeks after randomisation, and will carry out
further brief telephone surveys for long-term follow-up
at 6 months, 1 year and 2 years postintervention. Table 2
lists the study variables and timing for measurement.
The HVRF personnel are independent of the research
team, and interviews will be conducted within a super-
vised environment where interviewer performance is
regularly monitored to ensure scripts are read as written.
All survey questions use standardised wording, and the
questions are designed such that the woman’s study
group allocation is unclear to the interviewer until the
ﬁnal part of the interview.
Outcome measures
Primary outcome
The primary outcome is informed choice—that is, the
extent to which women’s screening decisions are consist-
ent with their informed values or attitudes.45 46
Informed choice is assessed by combining measures of
knowledge, attitudes and actual choice,47 and has been
used successfully in previous decision aid studies.36 38 48
Selection of this primary outcome reﬂects recent inter-
national commitments to informed choice as a key
marker of quality in screening programmes.
Informed choice will be assessed at 2 weeks postinter-
vention as a dichotomous outcome, and the intervention
and control groups will be compared in terms of the
proportion of women making an informed choice. To
determine whether each woman makes an informed
choice we will separately measure, and then combine,
three components: knowledge, attitudes and intentions.
An informed choice is one in which knowledge is
adequate, with attitudes and intentions being consistent
(ie, positive attitudes with positive intentions or negative
attitudes with negative intentions). For the purposes of
assessing informed choice, the knowledge, attitude and
intention measures will be dichotomised using an a
priori threshold (see below). The three component vari-
ables will also be examined and reported separately to
enable more ﬁne-grained understanding of the impact
of the intervention on decision-making.
Screening knowledge
We will apply a competency-based approach to assess
knowledge49 in line with our published knowledge
assessment framework.50 Understanding of conceptual
and numerical information provided in the study will be
measured using items adapted from our previous deci-
sion aid trials.36 38 The items are designed to assess
understanding of core screening concepts (including
Table 1 Summary of contents of intervention and control booklets
Pg. Intervention booklet Pg. Control booklet
1 Front cover: title+image 1 Front cover: title+image
2 Introduction to purpose of booklet 2 Introduction to purpose of booklet
3 Introduction to content of booklet 3 Introduction to content of booklet
4 Mortality benefit: text+diagram 4 Mortality benefit: text+diagram
5 Overdetection: text+diagram
6 Overdetection: conceptual illustration
7 False positive results: text+diagram 5 False positive results: text+diagram
8 Q and A (including breast cancer treatments) 6 Q and A (including breast cancer treatments)
9 Q and A (re overdetection)
10 Summary table+references 7 Summary table+references
11 Glossary; further information sources 8 Back cover: glossary; further information sources
12 Back cover: blank
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mortality beneﬁt, false positives and overdetection) and
awareness of the approximate numbers of women
affected by particular outcomes. Total knowledge scores
will comprise four subscales: conceptual understanding
(of general and overdetection-related information) and
numerical understanding (general and overdetection
related). As in previous decision aid trials,36 38 39 48
knowledge will be scored using a marking scheme devel-
oped a priori. The threshold score to be considered
adequate for the purposes of determining informed
choice will also be set a priori. Women will have to dem-
onstrate a basic conceptual understanding of overdetec-
tion, false positives and the mortality beneﬁt from
screening to be considered as having adequate knowl-
edge. Sensitivity analyses will examine the impact of
using higher and lower thresholds.
Screening attitudes
As at baseline, screening attitudes will be measured
using a validated six-item scale.42 Scores on each item
range from 1 (strongly negative) to 5 (strongly posi-
tive).36 For the informed choice outcome, the threshold
for a positive attitude will be a total score of 24 or above
(ie, scores of 4 or 5 on the 5-point response scale for
each item). As literature shows that screening attitudes
are typically very positive,36 38 39 a sensitivity analysis will
explore the impact of using a higher threshold.
Screening intentions
Intentions to participate in screening within the next 2–
3 years will be measured as described at baseline.40 41
Scores will be dichotomised on the ﬁve-point scale as
categories 1–3 (responses deﬁnitely will not, will not and
unsure) indicating ‘not intending’ to screen and categories
4–5 (will and deﬁnitely will) as ‘intending’ to screen.
Secondary outcomes
The following outcomes will be measured at 2 weeks
postintervention.
Perceived importance of screening benefit/harms
Purpose-developed items will be used to ask women
about their personal perceptions of the importance of
speciﬁc screening outcomes in their decision-making
about screening. Women will be asked how important it
is for them to consider the chances of (1) avoiding
breast cancer death, (2) being diagnosed and treated
for a cancer that is not harmful, and (3) having a false
positive. The four response options range from very
important to not at all important.
Perceived personal chances of screening benefit/harms
Women will be asked about their perceived personal
likelihood of experiencing speciﬁc outcomes (as above)
if they have screening, compared with an average
screened woman,51 using ﬁve verbal response categories
ranging from much lower to much higher.
Decision process
Decisional conﬂict and conﬁdence will be assessed using
the validated and widely used Decisional Conﬂict Scale
(10-item low literacy version)36 52 and Decision Self-
Efﬁcacy Scale.36 53
Table 2 Summary of study variables and timing for measurement
CALL # 1 2 3 4 5 6
Time from baseline −1 week BASELINE 2 weeks 6 months 1 year 2 years
Recruitment x
Demographics x
Stage of decision-making x
Screening intentions x x x
Screening attitudes x x x x
Screening knowledge (conceptual) x x x x
Screening knowledge (numerical) x x x
Overdetection knowledge (conceptual) x x x
Overdetection knowledge (numerical) x x x
Perceived importance of benefit/harms x
Perceived chances of benefit/harms x
Booklet utilisation/acceptability x
Decision process x
Time perspective x
Anticipated regret x x
Perceived risk of breast cancer x x x x
Breast cancer worry x x x x
Anxiety x x x x
Screening participation x x x
Decision regret x x x
Quality of life x x x
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Time perspective
This will be assessed using the four-item short form of
the Consideration of Future Consequences Scale,54 55
with ﬁve response categories ranging from strongly agree
to strongly disagree.
Anticipated regret
Two items from a validated scale will measure antici-
pated regret about screening (action regret) and about
not screening (inaction regret),56 57 with ﬁve response
categories ranging from strongly agree to strongly disagree.
Perceived personal risk of breast cancer
Women will be asked about their perceptions of per-
sonal risk for developing breast cancer in their lifetime,
in absolute terms57 (using four verbal response categor-
ies ranging from no chance to high chance) and relative to
an average woman of the same age58 (using ﬁve verbal
response categories ranging from much lower to much
higher).
Breast cancer worry
A validated single item will measure women’s level of
worry about developing breast cancer, using four verbal
response categories ranging from not worried at all to very
worried.36 38 59
Anxiety
This will be measured with the six-item short form of
the Spielberger State Trait Anxiety Inventory.36 56 60
Booklet utilisation and acceptability
Acceptability and utilisation of materials will be assessed
by items measuring how women used and evaluated the
booklets, as used successfully in previous decision aid
trials.39 61
The following secondary outcomes will be measured
at longer term follow-up.
Screening participation
Self-reported attendance at breast screening will be
assessed via telephone survey at 6 months, 1 and 2 years.
Previous research has demonstrated that this is a reliable
indicator of actual breast screening behaviour in
Australia (91% of women reported a mammogram
accurately to within a year of the recorded date).62
Attendance at diagnostic mammograms and other breast
tests will also be assessed by self-report at these time
points, and any relevant diagnoses will be recorded. At
the end of the trial we intend to assess participants’
screening attendance from screening records as well.
Decision regret
At 6 months, 1 and 2 years, the Decision Regret Scale63
will measure women’s level of regret regarding their
initial decision whether to screen or not. The scale has
ﬁve items and ﬁve response categories ranging from
strongly agree to strongly disagree.
Quality of life
At each of the long-term follow-up contacts, quality of life
will be measured using the Consequences of Screening
in Breast Cancer questionnaire, part I.64
Screening knowledge, attitudes, intentions and psychosocial
outcomes measured previously
Long-term follow-up contacts will reassess selected out-
comes using the same measures as previously (see table 2
for details).
Sample size
The primary analysis will be comparing the two study
groups on the proportion of women who make an
informed choice, using the χ2 test. We judge an absolute
difference of 10–15% to be relevant. Assuming conserva-
tively that one of the group proportions is 50%, in order
to achieve 80% power to detect a group difference of
10% with a two-sided signiﬁcance level of 5%, we
require 407 women per arm at the 2-week follow-up.
This sample size is sufﬁcient to detect a 10–15% differ-
ence in intentions and a mean difference smaller than
0.5 SDs in knowledge, attitudes and psychosocial out-
comes (assuming SDs for these scales based on results
from our previous trials) which is considered the
minimum clinically important difference for psycho-
social outcomes.65
On the basis of our previous research using a similar
protocol36 and data from HVRF, we anticipate losing
10% of recruited women at the preintervention stage
because they do not read initial study materials within
the required time frame, and up to a further 10% who
cannot be contacted for the 2-week follow-up survey.
Therefore to achieve our 2-week follow-up target sample
of 814 women in the quantitative stream and 60 in the
qualitative stream (see below) we aim to recruit approxi-
mately 1078 women into the study.
On the basis of their extensive telephone survey
experience, HVRF have estimated a further 20% loss to
follow-up at 1 year and an additional 10% at 2 years
(total loss to follow-up at 2 years is 30%). The remaining
sample should be sufﬁcient to detect a difference of
12% in attendance at 2 years among 285 women per
arm (assuming a 30% attrition rate and 47% attendance
rate at mammography screening).66
Statistical analysis methods
Analysis will compare the intervention and control
groups on an intention to treat basis (ie, all participants,
as randomised) and will be carried out blinded to inter-
vention status. We will use the χ2 test to analyse binary
outcomes including informed choice, and the two-
sample t test for continuous outcomes, with a signiﬁ-
cance level of 5%. We will use multiple imputation and
sensitivity analyses to explore the impact of missing data.
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STREAM B: QUALITATIVE STUDY
We will conduct a longitudinal qualitative evaluation
among women randomised to stream B of the trial to
explore in depth their responses to information about
overdetection—speciﬁcally, how they understand the
information and integrate it with existing knowledge,
and their subsequent intentions and decisions whether
to participate in screening. Women will receive an iden-
tical protocol to those in the main trial (stream A),
including quantitative telephone survey measures.
However, we will also carry out face-to-face or telephone
interviews among these women over 2 years at time
points corresponding with the assessment of self-
reported screening behaviour in the main randomised
controlled trial (6 months, 1 and 2 years). This will
enable us to examine the experience of screening
among women who choose to screen with and without
exposure to overdetection information (ie, intervention
and control groups), to assess whether the information
has any positive or negative impact on women’s screen-
ing experience (eg, the way in which women interpret,
cope with and act on their screening results). This will
allow a rich and contextualised understanding of
women’s experiences and decision-making to comple-
ment the quantitative data, and will also enable us to
examine the experience of women who choose not to
screen, including changes in their feelings over time
and following the receipt of screening invitations. Based
on current participation in BreastScreen we expect
between 25% and 50% of the women will choose not to
be screened, giving us a meaningful sample of women
choosing to screen and not to screen within the qualita-
tive stream.
Methods of data collection
All women will be interviewed either face to face or by
telephone, 1–2 months postintervention, by an experi-
enced qualitative interviewer. Subsequent interviews will
be conducted by telephone. For participants living
outside the greater Sydney area all interviews will be by
telephone. Interviews will be audio recorded and tran-
scribed verbatim.
Sample size
The intended sample size in the qualitative stream is 60
participants, of whom approximately 30 will be rando-
mised to each study arm. This is a well-accepted sample
size in qualitative studies using in-depth interviews, sufﬁ-
cient to explore variation in experiences among partici-
pants.67 68
Qualitative analysis
The study will take a phenomenological perspective and
will use framework analysis,69 a widely used matrix-based
method of thematic analysis which has been applied suc-
cessfully in many published qualitative studies.70 71 This
method enables qualitative themes to be compared
within individuals (eg, a woman’s understanding of
overdetection and her psychological response to it) and
between individuals (eg, comparing women who choose
to screen and those who do not). It is particularly useful
when working in a large research team to facilitate trans-
parency and rigour in the analytic process, and inter-
pretation of research ﬁndings.
ETHICS AND DISSEMINATION
Consent will be provided over the telephone and docu-
mented by the HVRF interviewer. Explaining the study
and obtaining consent by telephone will facilitate com-
prehension and reduce the unnecessary burden entailed
in a written consent form. All HVRF telephone inter-
views are administered through a computer-assisted tele-
phone interview (CATI) programme. The CATI and
quality control processes used by HVRF ensure that
interviewers do not skip any statements while providing
information to respondents. Immediately after recruit-
ment, women will be sent plain-language written study
information to inform them of their right to refuse par-
ticipation or withdraw consent at any time, including
instructions for how to contact the researchers with
questions, withdraw from the study or make a complaint.
The results of the trial will be published in appropri-
ate journals, regardless of the outcomes. The trial will
be reported in accordance with the CONSORT
Statement.72
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